Cargando…

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

Detalles Bibliográficos
Autores principales:	Ingrasciotta, Ylenia, Lacava, Viviana, Marcianò, Ilaria, Giorgianni, Francesco, Tripepi, Giovanni, Arrigo, Graziella D’., Chinellato, Alessandro, Tari, Daniele Ugo, Santoro, Domenico, Trifirò, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350726/ https://www.ncbi.nlm.nih.gov/pubmed/32646385 http://dx.doi.org/10.1186/s12882-020-01891-w

Ejemplares similares

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ylenia, Ingrasciotta, et al.
Publicado: (2019)

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2016)

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013
por: Ingrasciotta, Ylenia, et al.
Publicado: (2015)

Analgesic drug use in elderly persons: A population-based study in Southern Italy
por: Ingrasciotta, Ylenia, et al.
Publicado: (2019)

Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2015)

Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease
por: Trifirò, Gianluca, et al.
Publicado: (2014)

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014
por: Marcianò, Ilaria, et al.
Publicado: (2018)

The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy
por: Ingrasciotta, Ylenia, et al.
Publicado: (2014)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Predictors of hyporesponsiveness to ESAs in peritoneal dialysis patients: the role of residual renal function
por: Roldão, Marisa, et al.
Publicado: (2022)

Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy
por: Ingrasciotta, Ylenia, et al.
Publicado: (2021)

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients
por: Sibbel, Scott P., et al.
Publicado: (2015)

ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage
por: Kuragano, Takahiro, et al.
Publicado: (2016)

Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia
por: Gembillo, Guido, et al.
Publicado: (2021)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2022)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries
por: Oppelt, Katja A., et al.
Publicado: (2021)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials
por: Di Lernia, Vito, et al.
Publicado: (2022)

Hidradenitis suppurativa and psoriasis: the odd couple
por: Macca, Laura, et al.
Publicado: (2023)

Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China
por: Sui, Zhun, et al.
Publicado: (2019)

Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy
por: Ingrasciotta, Ylenia, et al.
Publicado: (2023)

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
por: MALARA, Giovanna, et al.
Publicado: (2021)

Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy
por: Ingrasciotta, Ylenia, et al.
Publicado: (2021)

Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2019)

Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies
por: Crisafulli, Salvatore, et al.
Publicado: (2021)

ESA Workshop
por: Guyenne, T D
Publicado: (1987)

Esa sangre
por: Azuela, Mariano, 1873-1952

Ionomycin Treatment Renders NK Cells Hyporesponsive
por: Romera-Cárdenas, Gema, et al.
Publicado: (2016)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

NK Cell Hyporesponsiveness: More Is Not Always Better
por: Frutoso, Marie, et al.
Publicado: (2019)

Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids
por: Correia-Neves, Margarida, et al.
Publicado: (2022)

¡Escriba esa carta! /
por: Maitland, Iain
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_5c7bamngsjk2mobvdaj0fajtss